16 Jan 2026 - Higher affinity equals better bispecific antibodies but not better CAR Ts

Wonderful work by Sarah DiNapoli, MD, PhD, identified how the binding affinity of antibody affect their ability to kill cells expressing cancer-specific neoantigens. Showed a "discordant" requirement for affinity, where increasing the binding strength of antibody improved the performance of bispecific antibodies but unexpectedly reduced the effectiveness of CAR T cells. This suggests that therapies must be tailored based on mode of killing, as "stronger" binding is not always better for cell-based therapies targeting low-density cancer antigens. https://pubmed.ncbi.nlm.nih.gov/41542775/